

University of Dundee

DOCTOR OF MEDICINE

The Role of Proteomics in Colorectal Cancer Biomarker Discovery

Goodbrand, Sarah A.

Award date:
2015

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

TABLES

Table 1: % of cases and 5-year survival according to Dukes stage	8
Table 2: Overview of the literature for multi panel faecal DNA testing	34
Table 3: Characteristics of cancer patients included in this study	115
Table 4: Characteristics of control individuals included in this study	119
Table 5: CE parameters	132
Table 6: LC conditions for ITRAQ experiments on Orbitrap mass spectrometer	133
Table 7: MASCOT ITRAQ quantitation method	137
Table 8: MASCOT parameters for ITRAQ protein ID analysis	138
Table 9: MASCOT parameters for label free protein ID analysis	142
Table 10: MASCOT parameters for Gel QTRAP analysis	147
Table 11: Lectins and their corresponding elution buffer	148
Table 12: MASCOT parameters for ID of glycoproteins	150
Table 13: Comparison of serum depletion methods using QSTAR mass spectrometer	152
Table 14: Comparison of serum depletion methods using Orbitrap-XL mass spectrometer	154

Table 15: Comparison of protein precipitation/desalting methods	156
.....
Table 16: Comparison of peptide separation methods	158
.....
Table 17: Comparison of HPLC gradient length for electrospray analysis	162
.....
Table 18: Effect of EPI length on the number of peptides and proteins derived from a simple digest	163
.....
Table 19: Effect of EPI length on the number of peptides derived from an ITRAQ labelled serum digest	163
.....
Table 20: Comparison of normalised collision energy HCD parameters	164
.....
Table 21: Comparison of Orbitrap-XL and QSTAR mass spectrometers at ITRAQ quantitation	167
.....
Table 22: Error associated with ITRAQ experiments	168
.....
Table 23: Deregulated proteins and their ratios in CRC serum identified in the 4 biological replicates	170
.....
Table 24: Functional analysis of CRC pool identified proteins using ITRAQ	171
.....
Table 25: Significant deregulated proteins in ITRAQ Dukes stages A-C (Average values produced 3 biological replicates)	173
.....
Table 26: Total numbers of deregulated proteins by Dukes stage	182
.....
Table 27: Numbers of deregulated proteins in Dukes stages A-C identified in ITRAQ experiment	183
.....
Table 28: Label free analysis of CRC pool	187
.....

Table 29: Label free IDs for CRC experiment	195
Table 30: Label free analysis of Dukes samples	196
Table 31: Label free IDs for Dukes experiment	205
Table 32: Summary of the numbers of proteins from each dataset not mapped within IPA	208
Table 33: Mapped IDs for CRC iTRAQ	210
Table 34: Canonical pathways for CRC ITRAQ (Ingenuity Pathways Analysis)	212
Table 35: CRC ITRAQ networks	215
Table 36: Top canonical pathways for CRC label free (Ingenuity Pathways Analysis)	217
Table 37: Mapped IDs CRC label free	218
Table 38: CRC Label free networks	220
Table 39: Top 5 Canonical pathways for Dukes A ITRAQ (Ingenuity Pathways Analysis)	222
Table 40: Mapped IDs Dukes A ITRAQ	223
Table 41: Dukes A ITRAQ networks	230
Table 42: Top 5 Canonical pathways for Dukes B ITRAQ (Ingenuity Pathway Analysis)	232
Table 43: Mapped IDs Dukes B ITRAQ	233

Table 44: Dukes B ITRAQ networks	242
Table 45: Top 5 canonical pathways for Dukes C ITRAQ (Ingenuity Pathway Analysis)	244
Table 46: Mapped IDs Dukes C ITRAQ	245
Table 47: Dukes C ITRAQ networks	252
Table 48: Top 5 canonical pathways for Dukes label free (Ingenuity Pathway Analysis)	255
Table 49: Mapped IDs Dukes label free	256
Table 50: Dukes label free networks	262
Table 51: IPA biomarkers Dukes A	266
Table 52: IPA biomarkers Dukes B	269
Table 53: IPA biomarkers Dukes C	272
Table 54: Common Dukes ITRAQ biomarkers	275
Table 55: Proteins identified from CRC bands excised at D10-1 with their molecular and biological functions	278
Table 56: Proteins identified from CRC bands excised at D10-3 with their molecular and biological functions	279

Table 57: Proteins identified from CRC bands excised at D10-6 with their molecular and biological functions	279
Table 58: Proteins identified from control bands excised at C10-2 with their molecular and biological functions	280
Table 59: Proteins identified from control bands excised at C10-4	281
Table 60: Proteins identified from control bands excised at C10-5 with their molecular and biological functions	282
Table 61: Comparisons of ID-Gel ITRAQ and label free proteomics	284
Table 62: Lectin analysis of pooled CRC serum	285
Table 63: Jac CRC results	287
Table 64: WGA CRC results	289
Table 65: Con A CRC results	292
Table 66: Deregulated proteins CRC ITRAQ	337
Table 67: Dukes ITRAQ	352

FIGURES

Figure 1: CRC genetic pathways	10
Figure 2: Proteomic categories	46
Figure 3: Bottom up and Top down proteomics	48
Figure 4: Processes by which gas phase ions are generated	64
Figure 5: MALDI-TOF MS sample ionisation	66
Figure 6: TOF mass analyser	70
Figure 7: Quadrapole mass analyser	72
Figure 8: Quadrapole Ion trap	74
Figure 9: Orbitrap mass spectrometer	76
Figure 10: FITCR mass analyser	78
Figure 11: Schematic of ITRAQ reagent	87
Figure 12: Dynamic range of serum. Reproduced from Genway website	92
Figure 13: ROC curve. Reproduced from matrix science help pages	104

Figure 14: Comparison of antibody depletion columns using QSTAR mass spectrometer	153
Figure 15: Comparison of antibody columns using the Orbitrap-XL mass spectrometer	155
Figure 16: Venn diagram representing the overlap of identified proteins in the 4 peptide separation methods tested	159
Figure 17: UV chromatogram for Poly LC SCX column measured at 215mm.	160
Figure 18: UV chromatogram for Thermo SCX column measured at 215mm.	161
Figure 19: UV chromatogram for RP column measured at 215mm.	161
Figure 20: HCD 35%. MS/MS Fragmentation of ATEHLSTLSEK	165
Figure 21: HCD 45%. MS/MS Fragmentation of ATEHLSTSEK	165
Figure 22: HCD 55%. MS/MS Fragmentation of ATEHLSTSEK	166
Figure 23: PQD. MS/MS Fragmentation of ATEHLSTSEK	166
Figure 24: Protein classes of deregulated Dukes stage proteins	184
Figure 25: Biological functions of deregulated proteins	185
Figure 26: Molecular functions of deregulated proteins	186

Figure 27: Alignment of LC-MS data	188
Figure 28: Filtering of features experiment 1	189
Figure 29: Filtering of features experiment 2	189
Figure 30: Results review	190
Figure 31: PCA analysis experiment 1	191
Figure 32: PCA analysis experiment 2	191
Figure 33: Expression patterns experiment 1	192
Figure 34: Expression patterns experiment 2	192
Figure 35: Power calculation experiment 1	193
Figure 36: Power calculation experiment 2	193
Figure 37: Inclusion data	194
Figure 38: Alignment of LC-MS data	197
Figure 39: Filtering of features experiment 1	198
Figure 40: Filtering of features experiment 2	198

Figure 41: Results review	199
Figure 42: PCA analysis experiment 1	200
Figure 43: PCA analysis experiment 2	201
Figure 44: Expression patterns experiment 1	201
Figure 45: Expression patterns experiment 2	202
Figure 46: Power calculation experiment 1	202
Figure 47: Power calculation experiment 2	203
Figure 48: Inclusion data	204
Figure 49: Canonical pathways enriched in the differentially expressed proteins for CRC ITRAQ (Ingenuity Pathway Analysis)	211
Figure 50: Networks enriched in the differentially expressed proteins CRC ITRAQ (Ingenuity Pathway Analysis)	213
Figure 51: Canonical pathways enriched in the differentially expressed proteins for CRC label free (Ingenuity Pathway Analysis)	216
Figure 52: Networks enriched in the differentially expressed proteins CRC label free (Ingenuity Pathway Analysis)	219

Figure 53: Canonical pathways enriched in the differentially expressed proteins for Dukes A ITRAQ (Ingenuity Pathway Analysis)	221
Figure 54: Network 1 enriched in the differentially expressed proteins Dukes A ITRAQ (Ingenuity Pathway Analysis)	227
Figure 55: Network 2 enriched in the differentially expressed proteins Dukes A ITRAQ (Ingenuity Pathway Analysis).	228
Figure 56: Network 3 enriched in the differentially expressed proteins Dukes A ITRAQ (Ingenuity Pathway Analysis) Interleukins form a large part of this network	229
Figure 57: Canonical pathways enriched in the differentially expressed proteins for Dukes B ITRAQ (Ingenuity Pathway Analysis)	231
Figure 58: Network 1 enriched in the differentially expressed proteins Dukes B ITRAQ (Ingenuity Pathway Analysis)	238
Figure 59: Network 2 enriched in the differentially expressed proteins Dukes B ITRAQ (Ingenuity Pathway Analysis)	239
Figure 60: Network 3 enriched in the differentially expressed proteins Dukes B ITRAQ (Ingenuity Pathway Analysis).	240
Figure 61: Canonical pathways enriched in the differentially expressed proteins for Dukes C ITRAQ (Ingenuity Pathway Analysis)	243

Figure 62: Network 1 enriched in the differentially expressed proteins Dukes C ITRAQ (Ingenuity Pathway Analysis)	248
Figure 63: Network 2 enriched in the differentially expressed proteins Dukes C ITRAQ (Ingenuity Pathway Analysis).	249
Figure 64: Network 3 enriched in the differentially expressed proteins Dukes C ITRAQ (Ingenuity Pathway Analysis).	250
Figure 65: Canonical pathways enriched in the differentially expressed proteins for Dukes label free (Ingenuity Pathway Analysis)	254
Figure 66: Network 1 enriched in the differentially expressed proteins Dukes label free (Ingenuity Pathway Analysis).	259
Figure 67: Network 2 enriched in the differentially expressed proteins Dukes label free (Ingenuity Pathway Analysis).	260
Figure 68: Network 3 enriched in the differentially expressed proteins Dukes label free (Ingenuity Pathway Analysis)	261
Figure 69: ID gel analysis of pooled CRC serum	274
Figure 70: Proportion of proteins quantitated versus protein abundance	299